Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

Nature

Volumn 508, Issue 7495, 2014, Pages 222-227

  Huber, Kilian V M ^a   Salah, Eidarus ^b   Radic, Branka ^a   Gridling, Manuela ^a   Elkins, Jonathan M ^b   Stukalov, Alexey ^a   Jemth, Ann Sofie ^c   Göktürk, Camilla ^c   Sanjiv, Kumar ^c   Strömberg, Kia ^c   Pham, Therese ^c   Berglund, Ulrika Warpman ^c   Colinge, Jacques ^a   Bennett, Keiryn L ^a   Loizou, Joanna I ^a   Helleday, Thomas ^c   Knapp, Stefan ^b   Superti Furga, Giulio ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; K RAS PROTEIN; MEMBRANE PROTEIN; MTH1 PROTEIN; NUCLEOTIDE; UNCLASSIFIED DRUG; 8 OXODGTPASE; 8-OXODGTPASE; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RAS PROTEIN; SCH 51344;

BIOTRANSFORMATION; CANCER; CATALYSIS; CATALYST; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; DRUG; ENZYME ACTIVITY; GENE EXPRESSION; HOMEOSTASIS; ORGANIC COMPOUND; TUMOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CRYSTAL STRUCTURE; DRUG TARGETING; ENANTIOMER; ENZYMATIC ASSAY; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEOMICS; STEREOSPECIFICITY; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; COLON TUMOR; CRYSTALLIZATION; DISEASE MODEL; DNA REPAIR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME SPECIFICITY; FEMALE; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PROTEIN CONFORMATION; SCID MOUSE; SINGLE STRANDED DNA BREAK;

ANIMALIA;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; CRYSTALLIZATION; DISEASE MODELS, ANIMAL; DNA BREAKS, SINGLE-STRANDED; DNA REPAIR; DNA REPAIR ENZYMES; FEMALE; HOMEOSTASIS; HUMANS; MICE; MICE, SCID; MODELS, MOLECULAR; NUCLEOTIDES; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEOMICS; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RAS PROTEINS; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899619048     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13194     Document Type: Article

References (33)

1. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nature Rev. Cancer 11, 761-774 (2011).
2. Parada, L. F., Tabin, C. J., Shih, C. & Weinberg, R. A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474-478 (1982).
3. Der, C. J., Krontiris, T. G.&Cooper, G. M. Transforming genes ofhuman bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl Acad. Sci. USA 79, 3637-3640 (1982).
4. Dekker, F. J. et al. Small-molecule inhibition of APT1 affects Ras localization and signaling. Nature Chem. Biol. 6, 449-456 (2010).
5. Xu, J. et al. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood 119, 1032-1035 (2012).
6. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEd interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
7. Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltagedependent anion channels. Nature 447, 865-869 (2007).
8. Kumar, C. C. et al. SCH 51344 inhibits ras transformation by a novel mechanism. Cancer Res. 55, 5106-5117 (1995).
9. Walsh, A. B., Dhanasekaran, M., Bar-Sagi, D. & Kumar, C. C. SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway. Oncogene 15, 2553-2560 (1997).
10. Rai, P. et al. Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence. Oncogene 30, 1489-1496 (2011).
11. Barbie, D. A. et al. SystematicRNAinterference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
12. Fujikawa, K. et al. The oxidized forms of dATP are substrates for the human MutT homologue, the hMTH1 protein. J. Biol. Chem. 274, 18201-18205 (1999).
13. Oka, S. et al. Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAs. EMBO J. 27, 421-432 (2008).
14. Yoshimura, D. et al. An oxidized purine nucleoside triphosphatase, MTH1, suppresses cell death caused by oxidative stress. J. Biol. Chem. 278, 37965-37973 (2003).
15. Svensson, L. M. et al. Crystal structure of human MTH1 and the 8-oxo-dGMP product complex. FEBS Lett. 585, 2617-2621 (2011).
16. Rai, P. et al. Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence. Proc. Natl Acad. Sci. USA 106, 169-174 (2009).
17. Fedorov, O. et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem. Biol. 18, 67-76 (2011).
18. Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342-6363 (2011).
19. Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007).
20. Camidge, D. R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011-1019 (2012).
21. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
22. Gerber, D. E. & Minna, J. D. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18, 548-551 (2010).
23. Butrynski, J. E. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727-1733 (2010).
24. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
25. Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23, 329-336 (2005).
26. Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628-1640 (2011).
27. Sakumi, K. et al. Ogg1 knockout-associated lung tumorigenesis and its suppression by Mth1 gene disruption. Cancer Res. 63, 902-905 (2003).
28. Speina, E. et al. Contribution of hMTH1 to the maintenance of 8-oxoguanine levels in lungDNAofnon-small-cell lungcancerpatients. J.Natl Cancer Inst. 97, 384-395 (2005).
29. Kennedy, C. H., Cueto, R., Belinsky, S. A., Lechner, J. F.&Pryor, W. A. Overexpression of hMTH1mRNA: a molecularmarker of oxidative stress in lung cancer cells. FEBS Lett. 429, 17-20 (1998).
30. Okamoto, K. et al. Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer. Int. J. Cancer 65, 437-441 (1996).
31. Tsuzuki, T. et al. Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase. Proc. Natl Acad. Sci. USA 98, 11456-11461 (2001).
32. Hutt, A. J. Chirality and pharmacokinetics: an area of neglected dimensionality? Drug Metabol. Drug Interact. 22, 79-112 (2007).
33. Aksoy, O. et al. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev. 26, 1546-1557 (2012).